A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
for Relapsed or Refractory Multiple Myeloma (RRMM)
22 locations incl. Birmingham
Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Sex: All·Age: 18+
Code: NCT06615479·Phase 3·Recruiting